Mylan Demands FDA Response To Petition On "Branded Generics"

Law360, New York (July 1, 2004, 12:00 AM EDT) -- U.S. generic drug maker Mylan Laboratories has supplemented a petition with the U.S. Food and Drug Administration, seeking an immediate response to its claim that branded drugmakers are unfairly undermining sales of generic drugmakers.

Mylan’s "citizens petition," submitted to the FDA in February, calls for the FDA to prevent makers of branded drugs from marketing their drugs as so-called "authorized generics.”

In its petition, Mylan requested that the FDA "prohibit the marketing and distribution of 'authorized generic' versions of brand name drugs until the expiration of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.